Summit to Highlight Potential of Precision Antibiotic Ridinilazole to Treat C. difficile Infection and Reduce Recurrent Disea...
26 Septembre 2018 - 9:00AM
Summit Therapeutics plc (‘Summit’ or the
’Company’)
Summit to Highlight Potential of Precision Antibiotic
Ridinilazole to Treat C. difficile Infection and Reduce Recurrent
Disease at ID Week 2018
Oxford, UK, and Cambridge, MA, US, 26
September 2018 – Summit Therapeutics plc (NASDAQ: SMMT, AIM:
SUMM), a leader in new mechanism antibiotic innovation, announces
that it will present data on its Phase 3-ready precision antibiotic
ridinilazole for the treatment of C. difficile infection at ID
Week, 3-7 October 2018 in San Francisco, CA.
Details of the presentations are below.
Oral Presentation
Title: Ridinilazole (RDZ) for Clostridium
difficile infection (CDI): Correlation of In Vitro Spectrum of
Activity with Human Gut Microbiome Profiles from a Phase 2 Clinical
TrialSession: Oral Abstract Session: Translating Microbiome
Science into PracticeDate: 6 October 2018, 11:15AM
PDTLocation: W 2002Authors: Richard Vickers, Ellie J
C Goldstein, Diane Citron, David Snydman, Cheleste M. Thorpe and
Anne V. Kane
Poster Presentations
Title: Combined Analysis of the In Vitro
Activity of Ridinilazole (RDZ) Against More Than
500 Clostridium difficile (CD) Clinical Isolates and
Impact of RDZ on Cell MorphologySession: Poster Abstract
Session: Novel AgentsDate: 5 October 2018Location: S
Poster HallAuthors: Esther Duperchy, Eugénie Bassères, Kevin
Garey, and Richard Vickers
Title: Pharmacokinetics and Safety of
Ridinilazole (RDZ), a Potential New Therapy for Clostridium
difficile Infection (CDI): from Animal Models to
PatientsSession: Poster Abstract Session: Novel
AgentsDate: 5 October 2018Location: S Poster
HallAuthors: Esther Duperchy, Sumita Chowdhury, Richard
Vickers, and Neil Robinson
Title: Ridinilazole (RDZ)
for Clostridium difficile Infection (CDI): Impact of
Diagnostic Method on Outcomes from a Phase 2 Clinical
TrialSession: Poster Abstract Session: Novel
AgentsDate: 5 October 2018Location: S Poster
HallAuthors: Richard Vickers, Sumita Chowdhury, and Mark
Wilcox
Title: Selecting Clostridium
difficile Infection (CDI) Outcome Measures Relevant to Public
Health Concerns: Experience From a Ridinilazole (RDZ) Phase 2
TrialSession: Poster Abstract Session: Treatment of AMR
InfectionsDate: 6 October 2018Location: S Poster
HallAuthors: Richard Vickers and Sumita Chowdhury
Copies of the presentations will be made
available on the Company’s website, www.summitplc.com, at the start
of each session.
About Summit Therapeutics Summit
Therapeutics is a leader in antibiotic innovation. Our new
mechanism antibiotics are designed to become the new standards of
care for the benefit of patients, and create value for payors and
healthcare providers. We are currently developing new mechanism
antibiotics for C. difficile infection and gonorrhoea and are using
our proprietary Discuva Platform to expand our pipeline. For more
information, visit www.summitplc.com and follow us on Twitter
@summitplc.
Contacts
Summit |
|
|
Glyn Edwards / Richard Pye (UK
office) |
Tel: |
44 (0)1235 443 951 |
Erik Ostrowski / Michelle Avery (US
office) |
|
+1 617 225 4455 |
|
|
|
Cairn Financial Advisers LLP
(Nominated Adviser) |
Tel: |
+44 (0)20 7213 0880 |
Liam Murray / Tony Rawlinson |
|
|
|
|
|
N+1 Singer (Joint Broker) |
Tel: |
+44 (0)20 7496 3000 |
Aubrey Powell / Jen Boorer, Corporate
FinanceTom Salvesen, Corporate Broking |
|
|
|
|
|
Panmure Gordon (Joint Broker) |
Tel: |
+44 (0)20 7886 2500 |
Freddy Crossley, Corporate FinanceJames
Stearns, Corporate Broking |
|
|
|
|
|
MSL Group (US) |
Tel: |
+1 781 684 6557 |
Jon Siegal |
|
summit@mslgroup.com |
|
|
|
Consilium Strategic Communications
(UK) |
Tel: |
+44 (0)20 3709 5700 |
Mary-Jane Elliott / Jessica Hodgson / |
|
summit@consilium-comms.com |
Lindsey Neville |
|
|
Summit Forward-looking Statements
Any statements in this press release about the
Company’s future expectations, plans and prospects, including but
not limited to, statements about the potential benefits of the
CARB-X award, including whether the option segments will be
exercised, the clinical and preclinical development of the
Company’s product candidates, the therapeutic potential of the
Company’s product candidates, the potential commercialisation of
the Company’s product candidates, the sufficiency of the Company’s
cash resources, the timing of initiation, completion and
availability of data from clinical trials, the potential submission
of applications for marketing approvals and other statements
containing the words "anticipate," "believe," "continue," "could,"
"estimate," "expect," "intend," "may," "plan," "potential,"
"predict," "project," "should," "target," "would," and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including: the uncertainties inherent in the initiation of
future clinical trials, availability and timing of data from
ongoing and future clinical trials and the results of such trials,
whether preliminary results from a clinical trial will be
predictive of the final results of that trial or whether results of
early clinical trials or preclinical studies will be indicative of
the results of later clinical trials, expectations for regulatory
approvals, laws and regulations affecting government contracts and
funding awards, availability of funding sufficient for the
Company’s foreseeable and unforeseeable operating expenses and
capital expenditure requirements and other factors discussed in the
"Risk Factors" section of filings that the Company makes with the
Securities and Exchange Commission, including the Company’s Annual
Report on Form 20-F for the fiscal year ended 31 January 2018.
Accordingly, readers should not place undue reliance on
forward-looking statements or information. In addition, any
forward-looking statements included in this press release represent
the Company’s views only as of the date of this release and should
not be relied upon as representing the Company’s views as of any
subsequent date. The Company specifically disclaims any obligation
to update any forward-looking statements included in this press
release.
-END-
Summit Therapeutics (NASDAQ:SMMT)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
Summit Therapeutics (NASDAQ:SMMT)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024